Michael Urban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael Urban has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Eva Hamsikova
Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
1 shared publication Jan Hrbáček
FNKV Praha
1 shared publication- Jan Hrbáček
Department of Urology, 2 Faculty of Medicine and Motol University Hospital, Charles University Praha, Czech Republic
1 shared publication - Jiri Heracek
Univerzita Karlova V Praze, Prague, Czech Republic
1 shared publication Jiří Heráček
FNKV Praha
1 shared publication- Marek Brabec
Institute of Computer Science of the Czech Academy of Sciences, Prague 8, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 3 February 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 53
Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study
Background: Infection plays a role in the pathogenesis of many human malignancies. Whether prostate cancer (PCa) - an important health issue in the aging male population in the Western world - belongs to these conditions has been a matter of research since the 1970 s. Persistent serum antibodies are a proof of present or past infection. The aim of this study was to compare serum antibodies against genitourinary infectious agents between PCa patients and controls with benign prostate hyperplasia (BPH). We hypothesized that elevated serum antibody levels or higher seroprevalence in PCa patients would suggest an association of genitourinary infection in patient history and elevated PCa risk. Methods: A total of 434 males who had undergone open prostate surgery in a single institution were included in the study: 329 PCa patients and 105 controls with BPH. The subjects' serum samples were analysed by means of enzyme-linked immunosorbent assay, complement fixation test and indirect immunofluorescence for the presence of antibodies against common genitourinary infectious agents: human papillomavirus (HPV) 6, 11, 16, 18, 31 and 33, herpes simplex virus (HSV) 1 and 2, human cytomegalovirus (CMV), Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum, Neisseria gonorrhoeae and Treponema pallidum. Antibody seroprevalence and mean serum antibody levels were compared between cases and controls. Tumour grade and stage were correlated with serological findings. Results: PCa patients were more likely to harbour antibodies against Ureaplasma urealyticum (odds ratio (OR) 2.06; 95% confidence interval (CI) 1.08-4.28). Men with BPH were more often seropositive for HPV 18 and Chlamydia trachomatis (OR 0.23; 95% CI 0.09-0.61 and OR 0.45; 95% CI 0.21-0.99, respectively) and had higher mean serum CMV antibody levels than PCa patients (p = 0.0004). Among PCa patients, antibodies against HPV 6 were associated with a higher Gleason score (p = 0.0305). Conclusions: Antibody seropositivity against the analyzed pathogens with the exception of Ureaplasma does not seem to be a risk factor for PCa pathogenesis. The presence or higher levels of serum antibodies against the genitourinary pathogens studied were not consistently associated with PCa. Serostatus was not a predictor of disease stage in the studied population.
- 3 February 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 53
Open AccessSerum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study
Background: Infection plays a role in the pathogenesis of many human malignancies. Whether prostate cancer (PCa) - an important health issue in the aging male population in the Western world - belongs to these conditions has been a matter of research since the 1970 s. Persistent serum antibodies are a proof of present or past infection. The aim of this study was to compare serum antibodies against genitourinary infectious agents between PCa patients and controls with benign prostate hyperplasia (BPH). We hypothesized that elevated serum antibody levels or higher seroprevalence in PCa patients would suggest an association of genitourinary infection in patient history and elevated PCa risk. Methods: A total of 434 males who had undergone open prostate surgery in a single institution were included in the study: 329 PCa patients and 105 controls with BPH. The subjects' serum samples were analysed by means of enzyme-linked immunosorbent assay, complement fixation test and indirect immunofluorescence for the presence of antibodies against common genitourinary infectious agents: human papillomavirus (HPV) 6, 11, 16, 18, 31 and 33, herpes simplex virus (HSV) 1 and 2, human cytomegalovirus (CMV), Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum, Neisseria gonorrhoeae and Treponema pallidum. Antibody seroprevalence and mean serum antibody levels were compared between cases and controls. Tumour grade and stage were correlated with serological findings. Results: PCa patients were more likely to harbour antibodies against Ureaplasma urealyticum (odds ratio (OR) 2.06; 95% confidence interval (CI) 1.08-4.28). Men with BPH were more often seropositive for HPV 18 and Chlamydia trachomatis (OR 0.23; 95% CI 0.09-0.61 and OR 0.45; 95% CI 0.21-0.99, respectively) and had higher mean serum CMV antibody levels than PCa patients (p = 0.0004). Among PCa patients, antibodies against HPV 6 were associated with a higher Gleason score (p = 0.0305). Conclusions: Antibody seropositivity against the analyzed pathogens with the exception of Ureaplasma does not seem to be a risk factor for PCa pathogenesis. The presence or higher levels of serum antibodies against the genitourinary pathogens studied were not consistently associated with PCa. Serostatus was not a predictor of disease stage in the studied population.
- Open Access
- 1 January 2008
- Published by Care Comm in Czech Urology
- Vol. 12 (1) , 37-43
New surgical method of treatment for male urinary incontinence - ARGUS adjustable sling implantation
C?l:Vyhodnotit ??innost a bezpe?nost nov? chirurgick? l??by mu?sk? inkontinence s vyu?it?m Argus adjustable male slingu.Materi?l a metoda:U 21 pacient? pr?m?rn?ho v?ku 67,5 let s inkontinenc? II. a III. stupn? jsme implantovali Argus adjustabl...
- 1 January 2008
- Published by Care Comm in Czech Urology
- Vol. 12 (1) , 37-43
Open AccessNew surgical method of treatment for male urinary incontinence - ARGUS adjustable sling implantation
C?l:Vyhodnotit ??innost a bezpe?nost nov? chirurgick? l??by mu?sk? inkontinence s vyu?it?m Argus adjustable male slingu.Materi?l a metoda:U 21 pacient? pr?m?rn?ho v?ku 67,5 let s inkontinenc? II. a III. stupn? jsme implantovali Argus adjustabl...